Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …

… Antigens resulting from viral open reading frames in a cancer’s genome are an example
of a high-quality antigen. This may be the reason the subset of Merkel-cell carcinoma that is …

… phenomenon can also be influenced by genetic predisposition; for example, the presence
of a CTLA4 polymorphism (Y60C) has been shown to increase the risk of early onset Crohn’s …

Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

Rationale: The Severe Asthma Research Program cohort includes subjects with persistent
asthma who have undergone detailed phenotypic characterization. Previous univariate …

Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …